Department of Medical Oncology, Oscar Lambret Center, Lille, France.
General Oncology Department, Oscar Lambret Cancer Center, Lille, France.
Ann Surg Oncol. 2019 Oct;26(11):3526-3534. doi: 10.1245/s10434-019-07494-6. Epub 2019 Jul 23.
The benefits of systematic re-excision (RE) after initial unplanned excision (UE) of soft tissue sarcoma (STS) are unknown.
The aim of this study was to evaluate the impact of delayed RE versus systematic RE after UE on overall survival (OS), metastatic relapse-free survival (MRFS), local relapse-free survival (LRFS), and rate of amputation.
Patients who underwent complete UE, without metastasis or residual disease, for primary extremity or superficial STS between 2007 and 2013 were analyzed. The amputation rate, LRFS, MRFS, and OS were assessed in cases of systematic RE in sarcoma referral centers (Group A), systematic RE outside of community centers (Group B), or without RE (Group C).
Groups A, B, and C included 300 (48.2%), 71 (11.4%), and 251 (40.4%) patients, respectively. Median follow-up was 61 months and 5-year OS was 88.4%, 87.3%, and 88% in Groups A, B, and C, respectively (p = 0.22), while 5-year MFRS was 85.4%, 86.2%, and 84.9%, respectively (p = 0.938); RE (p = 0.55) did not influence MRFS. The 5-year LRFS was 83%, 73.5%, and 63.8% in Groups A, B and C, respectively (p = 0.00001). Of the 123 local recurrences observed, 0/28, 1/15, and 5/80 patients in Groups A, B, and C, respectively, required amputation (p = 0.41). Factors influencing LRFS were adjuvant radiotherapy [hazard ratio (HR) 0.21; p = 0.0001], initial R0 resection (HR 0.24, p = 0.0001), and Group A (HR 0.44; p = 0.01).
Systematic RE in sarcoma centers offers best local control but does not impact OS. Delayed RE at the time of local relapse, if any, could be an option.
在初始计划外切除(UE)软组织肉瘤(STS)后进行系统性再次切除(RE)的益处尚不清楚。
本研究旨在评估 UE 后延迟 RE 与系统性 RE 对总生存(OS)、转移性无复发生存(MRFS)、局部无复发生存(LRFS)和截肢率的影响。
分析了 2007 年至 2013 年间在原发性肢体或浅表 STS 行完全 UE(无转移或残留疾病)的患者。在肉瘤转诊中心(A 组)进行系统性 RE、在社区中心以外进行系统性 RE(B 组)或不进行 RE(C 组)的情况下,评估截肢率、LRFS、MRFS 和 OS。
A、B 和 C 组分别纳入 300(48.2%)、71(11.4%)和 251(40.4%)例患者。中位随访时间为 61 个月,A、B 和 C 组的 5 年 OS 分别为 88.4%、87.3%和 88%(p=0.22),5 年 MFRS 分别为 85.4%、86.2%和 84.9%(p=0.938);RE(p=0.55)并未影响 MRFS。A、B 和 C 组的 5 年 LRFS 分别为 83%、73.5%和 63.8%(p=0.00001)。在观察到的 123 例局部复发中,A、B 和 C 组分别有 0/28、1/15 和 5/80 例患者需要截肢(p=0.41)。影响 LRFS 的因素包括辅助放疗[风险比(HR)0.21;p=0.0001]、初始 R0 切除(HR 0.24,p=0.0001)和 A 组(HR 0.44;p=0.01)。
肉瘤中心的系统性 RE 可提供最佳局部控制,但不会影响 OS。如果发生局部复发,延迟到那时进行 RE 可能是一种选择。